Select Medical Holdings Corporation has 11 Schedule 13D or 13G filings on record since 2025-11-24. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 9.9% | 12,320,106 | SCHEDULE 13G/A, 2026-07-30 | 2026-06-30 |
| Glazer Capital, LLC | 8.67% | 10,744,069 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 0.1% | 165,144 | SCHEDULE 13G/A, 2026-04-08 | 2026-03-31 |
| Ortenzio Robert A | 0% | 0 | SCHEDULE 13D/A, 2026-07-01 | 2026-07-01 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| Vanguard Portfolio Management | 0% | 2,134 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
Purpose of Transaction (Item 4)
Ortenzio Robert A
Item 4 of the Original Schedule 13D is hereby amended and supplemented to incorporate the following: Closing On June 30, 2026, the Issuer announced the consummation of the transactions contemplated by the Merger Agreement. Effective July 1, 2026, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation. At the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (other than Rollover Shares, Shares owned by Parent or the Issuer (as treasury stock or otherwise) or any of their respective direct or indirect wholly-owned subsidiaries as of immediately prior to the Effective Time or Shares for which appraisal rights have been demanded properly in accordance with Section 262 of the General Corporation Law of the State of Delaware), was converted into the right to receive $16.50 per share in cash, without interest. The Shares were suspended from trading on the New York Stock Exchange (the "NYSE") effective as of the opening of trading on July 1, 2026. The NYSE has filed a Notification of Removal from Listing and/or Registration on Form 25 to delist the Shares and terminate the registration of all Shares under Section 12(b) of the Exchange Act. The description of the consummation of the transactions contemplated by the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is filed as Exhibit 99.4 to Amendment No. 2 and is incorporated …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-01; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-24 | Ortenzio Robert A | 11.3% | SCHEDULE 13D |
| 2026-02-23 | Ortenzio Robert A | 11.3% | SCHEDULE 13D/A |
| 2026-03-04 | Ortenzio Robert A | 11.3% | SCHEDULE 13D/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-08 | T. Rowe Price Associates, Inc. | 0.1% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.45% | SCHEDULE 13G |
| 2026-05-14 | Glazer Capital, LLC | 5.21% | SCHEDULE 13G |
| 2026-07-01 | Ortenzio Robert A | 0% | SCHEDULE 13D/A |
| 2026-07-30 | BlackRock, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Portfolio Management | 0% | SCHEDULE 13G/A |
| 2026-08-13 | Glazer Capital, LLC | 8.67% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Select Medical Holdings Corporation. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.